Genocea Biosciences Inc (NASDAQ:GNCA) CFO Jonathan Poole Sells 45,000 Shares

Genocea Biosciences Inc (NASDAQ:GNCA) CFO Jonathan Poole sold 45,000 shares of Genocea Biosciences stock in a transaction on Monday, July 24th. The stock was sold at an average price of $6.00, for a total transaction of $270,000.00. Following the transaction, the chief financial officer now directly owns 84,247 shares in the company, valued at $505,482. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Shares of Genocea Biosciences Inc (NASDAQ:GNCA) traded down 0.74% during trading on Friday, hitting $4.01. 134,991 shares of the company were exchanged. The stock’s market capitalization is $114.78 million. Genocea Biosciences Inc has a 1-year low of $3.28 and a 1-year high of $7.29. The company has a 50 day moving average of $5.00 and a 200-day moving average of $5.50.

Genocea Biosciences (NASDAQ:GNCA) last announced its earnings results on Wednesday, August 9th. The biotechnology company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by $0.08. On average, analysts forecast that Genocea Biosciences Inc will post ($1.98) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Genocea Biosciences Inc (NASDAQ:GNCA) CFO Jonathan Poole Sells 45,000 Shares” was originally published by BNB Daily and is the property of of BNB Daily. If you are viewing this news story on another site, it was illegally copied and republished in violation of US & international copyright and trademark laws. The original version of this news story can be viewed at https://www.baseball-news-blog.com/2017/08/19/genocea-biosciences-inc-nasdaqgnca-cfo-jonathan-poole-sells-45000-shares-of-stock-updated-updated-updated.html.

A number of hedge funds and other institutional investors have recently made changes to their positions in GNCA. Ameriprise Financial Inc. boosted its position in shares of Genocea Biosciences by 34.1% in the first quarter. Ameriprise Financial Inc. now owns 19,933 shares of the biotechnology company’s stock valued at $121,000 after buying an additional 5,068 shares during the last quarter. Keybank National Association OH purchased a new position in shares of Genocea Biosciences during the first quarter valued at about $147,000. JPMorgan Chase & Co. purchased a new position in shares of Genocea Biosciences during the first quarter valued at about $217,000. FMR LLC boosted its position in shares of Genocea Biosciences by 0.4% in the first quarter. FMR LLC now owns 4,274,804 shares of the biotechnology company’s stock valued at $26,033,000 after buying an additional 18,574 shares during the last quarter. Finally, Segantii Capital Management Ltd purchased a new position in shares of Genocea Biosciences during the first quarter valued at about $160,000. 55.20% of the stock is currently owned by institutional investors and hedge funds.

A number of equities analysts have issued reports on the stock. Zacks Investment Research raised shares of Genocea Biosciences from a “sell” rating to a “hold” rating in a report on Thursday. ValuEngine downgraded shares of Genocea Biosciences from a “hold” rating to a “sell” rating in a report on Tuesday, August 1st. Cowen and Company reaffirmed an “outperform” rating and set a $40.00 price objective on shares of Genocea Biosciences in a report on Tuesday, July 25th. Piper Jaffray Companies reaffirmed an “overweight” rating and set a $18.00 price objective (up from $17.00) on shares of Genocea Biosciences in a report on Tuesday, July 25th. Finally, Needham & Company LLC raised shares of Genocea Biosciences from a “hold” rating to a “buy” rating and set a $12.00 price objective on the stock in a report on Monday, July 24th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $16.52.

Genocea Biosciences Company Profile

Genocea Biosciences, Inc, is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses.

Receive News & Ratings for Genocea Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply